A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

NCT01432938 · Completed

Last updated 2026-05-28

This clinical trial tests how the diabetes medication dulaglutide affects the blood-thinning effects of warfarin in healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 28 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2011-09 · est. completion 2011-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01432938 ↗

Description as written by the study sponsor.

Warfarin is a commonly used drug to prevent the blood from clotting. The purpose of this study is to determine if dulaglutide (LY2189265) affects how warfarin works. The study involves two different treatments (Treatment 1: warfarin; Treatment 2: dulaglutide + warfarin) separated by a minimum washout period of 24 days. In Treatment 1, the participant will receive 10 milligrams (mg) of warfarin on Day 1. In Treatment 2, the participant will receive a 1.5-mg dose of dulaglutide (LY2189265) as an injection on Day 1 and then a 10 mg dose of warfarin on Day 3. Participants will be randomly assigned into different treatment sequences. Participants in Treatment Sequence A will receive Treatment 1 then Treatment 2. Participants in Treatment Sequence B will receive Treatment 2 then Treatment 1.

Treatments tested

dulaglutide also known as LY2189265 Biologic

Administered subcutaneously
Warfarin Drug

Administered orally

Main thing measured	Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01432938 ↗